U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients

Digestive Diseases and Sciences

Volumn 56, Issue 3, 2011, Pages 880-888

  Ho, Samuel B ^a,b   Aqel, Bashar ^c   Dieperink, Eric ^c   Liu, Shanglei ^a   Tetrick, Lori ^c   Falck Ytter, Yngve ^d   Decomarmond, Charles ^e   Smith, Coleman I ^f   McKee, Daniel P ^g   Boyd, William ^e   Kulig, Clark C ^h   Bini, Edmund J ^e   Pedrosa, Marcos C ⁱ  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA MEDICAL CENTER   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Minnesota Gastroenterology   (United States)

^g Northland Gastroenterology   (United States)

^h VA Eastern Colorado Healthcare System   (United States)

ⁱ VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Consensus interferon; Hepatitis C; Ribavirin; Veterans Affairs

Indexed keywords

CONSENSUS INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; BRAIN DISEASE; CELLULITIS; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; GOVERNMENT; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RETINOPATHY; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UNITED STATES; VETERAN; VIREMIA; VIRUS LOAD; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 79952451796     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1504-y     Document Type: Article

References (29)

1. GL Armstrong A Wasley EP Simard, et al. 2006 The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 705 714 16702586 (Pubitemid 46780630)
2. JB Wong GM McQuillan JG McHutchison, et al. 2000 Estimating future hepatitis C morbidity, mortality, and costs in the United States Am J Public Health 90 1562 1569 1:STN:280:DC%2BD3cvnvFWnuw%3D%3D 10.2105/AJPH.90.10.1562 11029989
3. NIH 2002 National Institutes of Health consensus development conference statement: management of hepatitis C: 2002 Hepatology 36 S3 S15
4. MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 1:CAS:528:DC%2BD3MXntF2qtb8%3D 10.1016/S0140-6736(01)06102-5 11583749 (Pubitemid 32913521)
5. MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047 12324553
6. IM Jacobson RS Brown Jr.B Freilich, et al. 2007 Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial Hepatology 46 971 981 1:CAS:528:DC%2BD2sXht1aksrzE 10.1002/hep.21932 17894303 (Pubitemid 350144761)
7. JG McHutchison EJ Lawitz ML Shiffman, et al. 2009 Peginterferon Alfa-2b or Alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 580 593 1:CAS:528:DC%2BD1MXps1Kjuro%3D 10.1056/NEJMoa0808010 19625712
8. EJ Bini N Brau S Currie, et al. 2005 Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. Veterans with chronic hepatitis C virus infection Am J Gastroenterol 100 1772 1779 10.1111/j.1572-0241.2005.41860.x 16086714 (Pubitemid 41648433)
9. LI Backus DB Boothroyd BR Phillips, et al. 2007 Predictors of response of US veterans to treatment for the hepatitis C virus Hepatology 46 37 47 1:CAS:528:DC%2BD2sXosVyltrk%3D 10.1002/hep.21662 17567830 (Pubitemid 47171919)
10. LM Blatt JM Davis SB Klein, et al. 1996 The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon J Interferon Cytokine Res 16 489 499 1:CAS:528: DyaK28XksFKqt7o%3D 10.1089/jir.1996.16.489 8836913 (Pubitemid 26306949)
11. ON Ozes Z Reiter S Klein, et al. 1992 A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities J Interferon Res 12 55 59 1:CAS:528:DyaK38XhsV2rsr8%3D 1573283 (Pubitemid 23071073)
12. SB Klein LM Blatt MW Taylor 1993 Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-alpha 2a J Interferon Res 13 341 347 1:CAS:528:DyaK3sXms1yksbs%3D 8301154 (Pubitemid 24353057)
13. SB Klein LM Blatt MW Taylor 1996 Cell surface binding characteristics correlate with consensus type I interferon enhanced activity J Interferon Cytokine Res 16 1 6 1:CAS:528:DyaK28XlsFWrsQ%3D%3D 10.1089/jir.1996.16.1 8640445 (Pubitemid 26022481)
14. S Kaiser H Hass M Gregor 2002 High dose induction therapy with consensus interferon and ribavirin for treatment-naive patients with hepatitis C Hepatology 36 362A 10.1016/S0168-8278(01)00285-9 (Pubitemid 34194796)
15. S Kaiser H Hass M Gregor 2004 Successful retreatment of peginterferon nonresponder patients with chronic hepatitis C with high dose consensus interferon induction therapy Gastroenterology 126 A668
16. MH Sjogren R Sjogren Jr.MF Lyons, et al. 2007 Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin Dig Dis Sci 52 1540 1547 1:CAS:528:DC%2BD2sXltlaqt7w%3D 10.1007/s10620-007-9757-9 17406822 (Pubitemid 46776512)
17. CB Leevy 2008 Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin Dig Dis Sci 53 1961 1966 1:CAS:528:DC%2BD1cXmtlynsLg%3D 10.1007/s10620-007-0076-y 18219576
18. BR Bacon ML Shiffman F Mendes, et al. 2009 Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results Hepatology 49 1838 1846 1:CAS:528:DC%2BD1MXotVCmtLg%3D 10.1002/hep.22871 19291790
19. T Berg M von Wagner S Nasser, et al. 2006 Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin Gastroenterology 130 1086 1097 1:CAS:528:DC%2BD28XksFWmuro%3D 10.1053/j.gastro.2006.02.015 16618403
20. JM Sanchez-Tapias M Diago P Escartin, et al. 2006 Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment Gastroenterology 131 451 460 1:CAS:528:DC%2BD28XpsFyks7g%3D 10.1053/j.gastro.2006.05.016 16890599 (Pubitemid 44142452)
21. PJ Pockros R Reindollar J McHutchinson, et al. 2003 The safety and tolerability of daily infergen plus ribavirin in the treatment of naive chronic hepatitis C patients J Viral Hepat 10 55 60 1:STN:280:DC%2BD3s7gtlyitA%3D%3D 10.1046/j.1365-2893.2003.00402.x 12558913 (Pubitemid 36237813)
22. S Kaiser B Lutze B Sauter, et al. 2007 Retreatment of HCV genotype 1 relapse patients to peginterferon/ribavirin therapy with an extended treatment regimen of 72 weeks with consensus interferon/ribavirin versus peginterferon alpha/ribavirin Hepatology 46 819A
23. B Pearlman C Ehleben 2009 Retreatment of chronic hepatitis C genotype 1 infected relapsers to peginterferon/ribavirin with consensus interferon/ribavirin or with extended duration therapy peginterferon/ribavirin Hepatology 50 686A
24. S Chainuvati SK Khalid S Kancir, et al. 2006 Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders J Viral Hepat 13 235 241 1:STN:280:DC%2BD283gsFOqsg%3D%3D 10.1111/j.1365-2893.2005.00681.x 16611189
25. A Knott E Dieperink ML Willenbring, et al. 2006 Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes Am J Gastroenterol 101 2254 2262 10.1111/j.1572-0241.2006.00731.x 17032190 (Pubitemid 44477552)
26. H Groom E Dieperink DB Nelson, et al. 2008 Outcomes of a hepatitis C screening program at a large urban VA Medical Center J Clin Gastroenterol 42 97 106 10.1097/MCG.0b013e31802dc56f 18097298
27. PY Kwo EJ Lawitz J McCone, et al. 2010 Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 705 716 1:CAS:528:DC%2BC3cXhtVymt7zP 10.1016/S0140-6736(10)60934-8 20692693
28. N Brau EJ Bini S Currie, et al. 2006 Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin J Viral Hepat 13 242 249 1:STN:280:DC%2BD283gsFOqsw%3D%3D 10.1111/j.1365-2893.2005.00682.x 16611190
29. SJ Hadziyannis H Sette Jr.TR Morgan, et al. 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355 1:CAS:528:DC%2BD2cXitlOktrg%3D 14996676